Ignite Creation Date:
2025-12-24 @ 10:57 PM
Ignite Modification Date:
2026-05-07 @ 9:18 AM
Study NCT ID:
NCT05756569
Status:
RECRUITING
Last Update Posted:
2025-07-28
First Post:
2023-02-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Sponsor:
Emory University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Bladder Squamous Cell Carcinoma | View |
| None | Locally Advanced Bladder Carcinoma | View |
| None | Malignant Renal Pelvis Neoplasm | View |
| None | Malignant Ureter Neoplasm | View |
| None | Malignant Urethral Neoplasm | View |
| None | Metastatic Bladder Carcinoma | View |
| None | Stage III Bladder Cancer AJCC v8 | View |
| None | Stage IV Bladder Cancer AJCC v8 | View |
| None | Unresectable Bladder Carcinoma | View |
| None | Urachal Adenocarcinoma | View |
| None | Bladder Adenocarcinoma | View |
Keywords: